Foundation Medicine Inc. (FMI)

85.80
NASDAQ : Health Technology
Prev Close 85.80
Day Low/High 0.00 / 0.00
52 Wk Low/High 31.70 / 88.75
Avg Volume 317.60K
Exchange NASDAQ
Shares Outstanding 37.04M
Market Cap 3.22B
EPS -4.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Foundation Medicine Announces Final National Coverage Determination (NCD) From The Centers For Medicare & Medicaid Services (CMS), Including Coverage For FoundationOne CDx™ Across All Solid Tumors

Foundation Medicine Announces Final National Coverage Determination (NCD) From The Centers For Medicare & Medicaid Services (CMS), Including Coverage For FoundationOne CDx™ Across All Solid Tumors

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the Centers for Medicare & Medicaid Services (CMS) issued a final National Coverage Determination (NCD) for patients who receive next generation sequencing...

Foundation Medicine Advances Patient Access To Precision Medicine; Pursues Regulatory Approval For FoundationOne CDx™ In Japan

Foundation Medicine Advances Patient Access To Precision Medicine; Pursues Regulatory Approval For FoundationOne CDx™ In Japan

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that Chugai Pharmaceutical Co.

Foundation Medicine And Guardant Health Agree To Resolve False Advertising Lawsuit

Foundation Medicine And Guardant Health Agree To Resolve False Advertising Lawsuit

Foundation Medicine, Inc. (NASDAQ:FMI) and Guardant Health, Inc.

Foundation Medicine To Present At Cowen And Company's 38th Annual Healthcare Conference

Foundation Medicine To Present At Cowen And Company's 38th Annual Healthcare Conference

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at Cowen & Company's 38 th Annual Healthcare Conference on Wednesday, March 14, 2018, at 10:40 a.

Foundation Medicine Announces 2017 Fourth Quarter And Year-End Results, Recent Highlights And 2018 Outlook

Foundation Medicine Announces 2017 Fourth Quarter And Year-End Results, Recent Highlights And 2018 Outlook

Foundation Medicine (NASDAQ:FMI) today reported financial and operational results for the fourth quarter and year ended December 31, 2017.

Foundation Medicine Announces Timing For Fourth Quarter And Year-End 2017 Financial Results And Conference Call

Foundation Medicine Announces Timing For Fourth Quarter And Year-End 2017 Financial Results And Conference Call

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's fourth quarter and year ended December 31, 2017 will be released on Wednesday, March 7, 2018.

Foundation Medicine And European Organisation For Research And Treatment Of Cancer (EORTC) Announce Collaboration To Advance Precision Medicine Using Comprehensive Genomic Profiling To Facilitate Clinical Trial Enrollment

Foundation Medicine And European Organisation For Research And Treatment Of Cancer (EORTC) Announce Collaboration To Advance Precision Medicine Using Comprehensive Genomic Profiling To Facilitate Clinical Trial Enrollment

Foundation Medicine, Inc. (NASDAQ:FMI) and the European Organisation for Research and Treatment of Cancer (EORTC) announced today a collaboration in which Foundation Medicine's comprehensive genomic profiling (CGP)...

Foundation Medicine And Pfizer Announce Broad Partnership To Develop Companion Diagnostics For Pfizer's Oncology Portfolio

Foundation Medicine And Pfizer Announce Broad Partnership To Develop Companion Diagnostics For Pfizer's Oncology Portfolio

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company has entered into a broad partnership with Pfizer Inc.

Foundation Medicine Reports Preliminary 2017 Results

Foundation Medicine Reports Preliminary 2017 Results

Foundation Medicine (NASDAQ:FMI) today announced preliminary unaudited total revenue of approximately $48.

Foundation Medicine To Present At The 36th Annual J.P. Morgan Healthcare Conference

Foundation Medicine To Present At The 36th Annual J.P. Morgan Healthcare Conference

Foundation Medicine today announced that Troy Cox, chief executive officer, is scheduled to present at the 36th Annual J.

Foundation Medicine And Collaborators To Present New Data At The American Society Of Hematology (ASH) Annual Meeting That Supports Use Of FoundationOne®Heme To Advance Personalized Medicine In Blood Cancers

Foundation Medicine And Collaborators To Present New Data At The American Society Of Hematology (ASH) Annual Meeting That Supports Use Of FoundationOne®Heme To Advance Personalized Medicine In Blood Cancers

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that new data generated with FoundationOne ® Heme, its comprehensive genomic profiling (CGP) assay for hematologic malignancies and sarcomas, will be...

Foundation Medicine's Next-generation Sequencing Laboratory (Photo: Business Wire)

Foundation Medicine's Next-generation Sequencing Laboratory (Photo: Business Wire)

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the U.

Foundation Medicine Announces 2017 Third Quarter Results And Recent Highlights

Foundation Medicine Announces 2017 Third Quarter Results And Recent Highlights

Foundation Medicine, Inc. (NASDAQ: FMI) today reported financial and operating results for its third quarter ended September 30, 2017.

Foundation Medicine To Present Validation For FoundationOne CDx™, A Comprehensive Genomic Profiling Assay For Advancing Precision Cancer Care

Foundation Medicine To Present Validation For FoundationOne CDx™, A Comprehensive Genomic Profiling Assay For Advancing Precision Cancer Care

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company will present validation data for FoundationOne CDx, its comprehensive genomic profiling assay, at the International Association for the Study of Lung...

Foundation Medicine Announces Timing For Third Quarter 2017 Financial Results And Conference Call

Foundation Medicine Announces Timing For Third Quarter 2017 Financial Results And Conference Call

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's third quarter ended September 30, 2017 will be released on Wednesday, November 1, 2017.

Foundation Medicine Appoints Tom Civik As Chief Commercial Officer

Foundation Medicine Appoints Tom Civik As Chief Commercial Officer

Foundation Medicine, Inc. (NASDAQ:FMI) today announced the appointment of Tom Civik to the role of chief commercial officer.

Foundation Medicine Receives Approval From The State Of New York For Its FoundationACT Liquid Biopsy Assay

Foundation Medicine Receives Approval From The State Of New York For Its FoundationACT Liquid Biopsy Assay

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that it received approval from the New York State (NYS) Clinical Laboratory Evaluation Program (CLEP) for its FoundationACT® blood-based circulating tumor DNA...

FOUNDATION MEDICINE 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors Of Deadline In Class Action Lawsuit Against Foundation Medicine, Inc. - (FMI)

FOUNDATION MEDICINE 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors Of Deadline In Class Action Lawsuit Against Foundation Medicine, Inc. - (FMI)

ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until September 26, 2017 to file lead plaintiff applications in a securities class action lawsuit against Foundation Medicine, Inc.

Glancy Prongay & Murray Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Foundation Medicine, Inc. (FMI)

Glancy Prongay & Murray Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Foundation Medicine, Inc. (FMI)

Glancy Prongay & Murray LLP ("GPM") reminds investors of the September 26, 2017 deadline in the class action lawsuit filed on behalf of investors who purchased Foundation Medicine, Inc.

Glancy Prongay & Murray LLP Commences Investigation On Behalf Of Foundation Medicine, Inc. Investors (FMI)

Glancy Prongay & Murray LLP Commences Investigation On Behalf Of Foundation Medicine, Inc. Investors (FMI)

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Foundation Medicine, Inc.

FOUNDATION MEDICINE SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Foundation Medicine, Inc. - (FMI)

FOUNDATION MEDICINE SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Foundation Medicine, Inc. - (FMI)

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 26, 2017 to file lead plaintiff applications in a securities class action lawsuit against Foundation Medicine, Inc.

Foundation Medicine To Present Validation Data For Its Assay Measuring Tumor Mutational Burden In Blood (bTMB), A New, Non-Invasive Predictor Of Response To Immunotherapy

Foundation Medicine To Present Validation Data For Its Assay Measuring Tumor Mutational Burden In Blood (bTMB), A New, Non-Invasive Predictor Of Response To Immunotherapy

Foundation Medicine, Inc. (NASDAQ:FMI) today announced presentations at the European Society for Medical Oncology (ESMO) Annual Meeting highlighting validation data for its novel assay to measure tumor mutational burden...

TheStreet Quant Rating: D (Sell)